233 related articles for article (PubMed ID: 30511936)
1. Interval cancers after negative immunochemical test compared to screen and non-responders' detected cancers in Slovenian colorectal cancer screening programme.
Mlakar DN; Bric TK; Škrjanec AL; Krajc M
Radiol Oncol; 2018 Jul; 52(4):413-421. PubMed ID: 30511936
[TBL] [Abstract][Full Text] [Related]
2. Incidence of interval cancers in faecal immunochemical test colorectal screening programmes in Italy.
Giorgi Rossi P; Carretta E; Mangone L; Baracco S; Serraino D; Zorzi M;
J Med Screen; 2018 Mar; 25(1):32-39. PubMed ID: 28195508
[TBL] [Abstract][Full Text] [Related]
3. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
[TBL] [Abstract][Full Text] [Related]
4. Interval colorectal cancers after negative faecal immunochemical test in a 13-year screening programme.
Zorzi M; Hassan C; Senore C; Capodaglio G; Turrin A; Narne E; Mussato A; Rizzato S; Chinellato E; Zamberlan S; Repici A; Rugge M
J Med Screen; 2021 Jun; 28(2):131-139. PubMed ID: 32393153
[TBL] [Abstract][Full Text] [Related]
5. Interval cancers in a guaiac-based colorectal cancer screening programme: Consequences on sensitivity.
Blom J; Törnberg S
J Med Screen; 2017 Sep; 24(3):146-152. PubMed ID: 28142309
[TBL] [Abstract][Full Text] [Related]
6. Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme.
van de Veerdonk W; Hoeck S; Peeters M; Van Hal G; Francart J; De Brabander I
United European Gastroenterol J; 2020 Mar; 8(2):185-194. PubMed ID: 32213071
[TBL] [Abstract][Full Text] [Related]
7. Impact of screening programme using the faecal immunochemical test on stage of colorectal cancer: Results from the IMPATTO study.
Vicentini M; Zorzi M; Bovo E; Mancuso P; Zappa M; Manneschi G; Mangone L; Giorgi Rossi P;
Int J Cancer; 2019 Jul; 145(1):110-121. PubMed ID: 30585621
[TBL] [Abstract][Full Text] [Related]
8. Improved 5-year survival of patients with immunochemical faecal blood test-screen-detected colorectal cancer versus non-screening cancers in northern Italy.
Parente F; Vailati C; Boemo C; Bonoldi E; Ardizzoia A; Ilardo A; Tortorella F; Cereda D; Cremaschini M; Moretti R
Dig Liver Dis; 2015 Jan; 47(1):68-72. PubMed ID: 25306524
[TBL] [Abstract][Full Text] [Related]
9. Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited.
Digby J; Fraser CG; Carey FA; Lang J; Stanners G; Steele RJ
J Med Screen; 2016 Sep; 23(3):130-4. PubMed ID: 26589788
[TBL] [Abstract][Full Text] [Related]
10. The impact of immunochemical faecal occult blood testing on colorectal cancer incidence.
Ventura L; Mantellini P; Grazzini G; Castiglione G; Buzzoni C; Rubeca T; Sacchettini C; Paci E; Zappa M
Dig Liver Dis; 2014 Jan; 46(1):82-6. PubMed ID: 24011791
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of latex agglutination faecal occult blood test in the Florence District population-based colorectal cancer screening programme.
Castiglione G; Visioli CB; Ciatto S; Grazzini G; Bonanomi AG; Rubeca T; Mantellini P; Zappa M
Br J Cancer; 2007 Jun; 96(11):1750-4. PubMed ID: 17453007
[TBL] [Abstract][Full Text] [Related]
12. Patterns of uptake in a biennial faecal occult blood test screening programme for colorectal cancer.
Steele RJ; McClements PL; Libby G; Carey FA; Fraser CG
Colorectal Dis; 2014 Jan; 16(1):28-32. PubMed ID: 24034143
[TBL] [Abstract][Full Text] [Related]
13. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology.
Bampton PA; Sandford JJ; Cole SR; Smith A; Morcom J; Cadd B; Young GP
Gut; 2005 Jun; 54(6):803-6. PubMed ID: 15888788
[TBL] [Abstract][Full Text] [Related]
14. Colorectal adenocarcinomas diagnosed following a negative faecal immunochemical test show high-risk pathological features in a colon screening programme.
Steel MJ; Bukhari H; Gentile L; Telford J; Schaeffer DF
Histopathology; 2021 Apr; 78(5):710-716. PubMed ID: 33037645
[TBL] [Abstract][Full Text] [Related]
15. A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population.
Wong BC; Wong WM; Cheung KL; Tong TS; Rozen P; Young GP; Chu KW; Ho J; Law WL; Tung HM; Lai KC; Hu WH; Chan CK; Lam SK
Aliment Pharmacol Ther; 2003 Nov; 18(9):941-6. PubMed ID: 14616158
[TBL] [Abstract][Full Text] [Related]
16. A comparison of tumour and host prognostic factors in screen-detected vs nonscreen-detected colorectal cancer: a contemporaneous study.
Mansouri D; McMillan DC; McIlveen E; Crighton EM; Morrison DS; Horgan PG
Colorectal Dis; 2016 Oct; 18(10):967-975. PubMed ID: 26859503
[TBL] [Abstract][Full Text] [Related]
17. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study.
Fraser CG; Matthew CM; Mowat NA; Wilson JA; Carey FA; Steele RJ
Lancet Oncol; 2006 Feb; 7(2):127-31. PubMed ID: 16455476
[TBL] [Abstract][Full Text] [Related]
18. Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study.
Breekveldt ECH; Lansdorp-Vogelaar I; Toes-Zoutendijk E; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers CRB; Dekker E; Nagtegaal ID; Krul MF; Kok NFM; Kuhlmann KFD; Vink GR; van Leerdam ME; Elferink MAG;
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):60-68. PubMed ID: 34822762
[TBL] [Abstract][Full Text] [Related]
19. Interval cancers in a community-based programme of colorectal cancer screening with faecal occult blood test.
Tazi MA; Faivre J; Lejeune C; Bolard P; Phelip JM; Benhamiche AM
Eur J Cancer Prev; 1999 Apr; 8(2):131-5. PubMed ID: 10335459
[TBL] [Abstract][Full Text] [Related]
20. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site.
Steele RJ; McClements P; Watling C; Libby G; Weller D; Brewster DH; Black R; Carey FA; Fraser CG
Gut; 2012 Apr; 61(4):576-81. PubMed ID: 21930729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
